Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Search History:
Count: 95
Selected: 0
NCT IDTitle
NCT02398058Trabectedin Plus Olaparib in Metastatic or Advanced Sarcomas (TOMAS)
NCT01876043Efficacy and Safety of Plitidepsin in Patients With Advanced Unresectable or Metastatic, Relapsed/Refractory, Dedifferentiated Liposarcoma (DLPS): an Exploratory Phase II Multicenter Trial
NCT02684318Study to Evaluate PM01183 in Combination With Olaparib in Advanced Solid Tumors
NCT01970540Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors
NCT00579501Safety and Efficacy Study of Trabectedin for the Treatment of Localized Myxoid / Round Cell Liposarcoma
NCT01980667Study of Lurbinectedin (PM01183) in Combination With Cisplatin in Patients With Solid Tumors
NCT05063318Clinical Trial of Lurbinectedin (PM01183) in Patients With Advanced Solid Tumors
NCT02451007Evaluation of the Effect of Lurbinectedin (PM01183) on Cardiac Repolarization in Patients With Selected Solid Tumors
NCT00060944A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer
NCT03070964A Study of Plitidepsin in Patients With Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma
NCT01102426Aplidin - Dexamethasone in Relapsed/Refractory Myeloma
NCT02825420Non-interventional European Study of Trabectedin + PLD in the Treatment of Relapsed Ovarian Cancer (ROC) Patients
NCT02454972Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors
NCT00884286Multicenter Trial to Treat Patients With Relapsed/Refractory Aggressive Non Hodgkin Lymphoma
NCT03284320Retrospective Study in Sarcoma Patients
NCT01299506Study in Patients With Advanced Soft Tissue Sarcoma (STS) After Failure of Anthracyclines and/or Ifosfamide
NCT05285033RW Effectiveness of Lurbinectedin in Extensive Stage SCLC
NCT02163720Ovarian Cancer Treatment Platinum-sensitive Relapse - Cohort Study (PROSPECTYON)
NCT02611024Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
NCT02100657Study of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Patients With Multiple Myeloma
NCT04784559Trial to Determine the Efficacy/Safety of Plitidepsin vs Control in Patients With Moderate COVID-19 Infection
NCT04305548Study on Trabectedin in Advanced Rearranged Mesenchymal Chondrosarcoma
NCT02367924Efficacy and Safety of Trabectedin (Yondelis®) in Patients With Advanced Soft Tissue Sarcoma
NCT06088290Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)
NCT01149681Clinical Trial of Aplidin® in Patients With Primary Myelofibrosis
NCT00359294A Phase I Study of Zalypsis (PM00104) in Subjects With Advanced Malignant Solid Tumors or Lymphoma
NCT00900562Clinical Trial of PM00104 (Zalypsis®) in Patients With Advanced and/or Metastatic Endometrial or Cervical Cancer Previously Treated With One Line of Systemic Chemotherapy
NCT02194231ATREUS - Phase II Study on the Activity of Trabectedin in Patients With Malignant Pleural Mesothelioma (MPM)
NCT01970553Escalating Doses of PM01183 in Combination With Gemcitabine in Patients With Specific Unresectable Solid Tumors
NCT04382066Proof of Concept Study to Evaluate the Safety Profile of Plitidepsin in Patients With COVID-19
NCT03427268Clinical Trial of PM60184 in Advanced Colorectal Cancer After Standard Treatment
NCT05121740Extension Study in a Cohort of Adult Patients With COVID-19 Infection
NCT00147212ET 743 (Yondelis) in Men With Advanced Prostate Cancer
NCT01273493A Pharmacokinetic Study of Trabectedin in Patients With Advanced Malignancies and Hepatic Dysfunction
NCT02809339Improving Quality of Care for Patients With Recurrent Ovarian Cancer
NCT01846611A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT01343277A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma
NCT03085225Trabectedin Combined With Durvalumab in Patients With Advanced Pretreated Soft-tissue Sarcomas and Ovarian Carcinomas.
NCT01314599Clinical Study of PM01183 in Patients With Acute Leukemia or Relapsed/Refractory Myelodysplastic Syndrome
NCT01735071Bevacizumab and Trabectedin +/- Carboplatin in Advanced Ovarian Cancer
NCT01222767Study of Zalypsis® (PM00104) in Patients With Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing After at Least One Prior Line of Chemotherapy
NCT01869400An Observational Study of YONDELIS®+PLD for the Treatment of Patients With Platinum-sensitive Relapse of Ovarian Cancer
NCT01951157A Clinical Study in Three-arm of Lurbinectedin (PM01183) Alone or in Combination With Gemcitabine and a Control Arm With Docetaxel as Second Line Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients
NCT06524583Interest of Post-operative Chemotherapy in Patients With Localised Uterine Leiomyosarcoma Suspected of Having a High Risk of Recurrence Based on a Biological Test Performed on the Tumour
NCT00050427A Study of ET-743 (Trabectedin) in Patients With Advanced Breast Cancer
NCT05076396PM14 Administered Intravenously to Patients with Advanced Solid Tumors
NCT05101265Clinical Pharmacokinetic Study of Lurbinectedin in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Impairment
NCT00027508Ecteinascidin 743 in Treating Patients With Malignant Mesothelioma
NCT02533674Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM060184 in Combination With Gemcitabine in Selected Patients With Advanced Solid Tumors
NCT01525589A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer